81% of Patients Improved Their EP Score by ONE Single Treatment

In September 2019, Chivalry Health conducted our first treatment efficacy testing with a group of 80 patients to collect our data, and the results were shown as follow: 

• 208 total patients
• 81% of the patients have significant improvement on lumber and cervical flexibility. Their pain and other symptoms released with large degrees​

All-round Improvement

Improvement of the first treatment

​There was a significant difference(​paired-samples t-test, p<0.0001) in scores before and after VSD treatment, the EP stress score improved 17%

​Left side and Right side Rebalancing

After the first 10 minutes treatment, the group of 208 patients left side and right side adjusted to the balanced EP score.

​Improvement in each spinal zone and the most improved zone

Each spinal zone shows significant improvement after the first treatment

Zone

C2

C4

C6

T1

T3

T5

T7

T9

T11

L1

L3

L5

Area

​Cervical

Cervical

Cervical

​Thoracic

​Thoracic

Thoracic

Thoracic

Thoracic

Thoracic

Lumbar

Lumbar

Lumbar

Improved

​24.4%

20.6%

11.4%

​​15.7%

13.2%

17.1%

16.0%

17.6%

15.1%

11.4%

17.1%

21.9%

​Spinal zones that have the most improvements are the following: 

​C2 Improved 24.4%                                                                                     
​L5  Improved 21.9%

Prevention based treatment​

Patients who have an EP Score lower than 150 (Mild to moderate spinal problem or back pain) improved 5.1% after one single treatment. This data shows that the treatment helps patients who are in the early stage of spinal problem reduce their back pain and maintain their spinal health for prevention purpose.    ​​

Therapeutic treatment

Patients who have EP Score higher than 200 (Severe back pain to injured Spine)  improved 20.8% after one single treatment. This data shows that VSD treatment gives more significant improvement to patients who are suffering from severe spinal problems or back pain.  ​

Historical Treatment testing and improvements ​

	​First Treatment Testing	Second Treatment Testing	​Third Treatment Testing
Number of Patients	85	154
Percentage of Improved Patients	80%	81%

​VSD is awaiting FDA approval and is not currently available in the United States
These results have been independently validated and have not been reviewed by the FDA